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This body of work arose from everyday challenges that paediatricians and neonatologists have working 
in the field of general paediatrics and neonatology regarding the implementation and use of the 
universal Group B Streptococcal (GBS) Screening and Management Guidelines. Despite universal 
screening programs for maternal GBS colonisation in pregnancy that have been instituted across 
hospitals in Australia, neonatal GBS infection remains the most common cause of infectious neonatal 
morbidity and mortality. This bacterium can illicit early onset disease occurring in the first week of life of 
the neonate, or late-onset disease occurring anywhere after the first week of life, up to the first three 
months causing major mortality and morbidity, often presenting as neurodevelopmental sequelae in 
affected infants. 
In Australia, most of our states and territories have adopted a version of the universal screening 
approach of pregnant mothers during week 35-37 of their pregnancy, for GBS colonisation. Depending 
on individual risk factors, maternal antibiotic prophylaxis is offered to mothers in labour in order to 
prevent neonatal GBS disease. Despite the universal recommendations to screen and manage this 
disease, the guidelines are often followed sporadically and left up to the clinician’s discretion. There is 
also a concern that the widespread use of maternal antibiotic prophylaxis is increasing worldwide 
antibiotic resistance of GBS strains and may lead to unwanted health issues in the longer term for the 
infant (such as increasing atopic and gastrointestinal disease).  
The first publication, ‘GBS Study Protocol’, describes the novel study design implemented for the 
comprehensive collection of retrospective data over a 16-year period across 5 hospitals in South 
Australia and the Northern Territory. Currently, notification of Group B streptococcal infections in the 
young infant is not mandatory. As a result, the true incidence of early onset and late onset GBS disease 
is not known in Australia. This case-control study was designed to measure the true incidence of both 
early onset and late onset GBS disease over the last 16 years in South Australia (SA) and the Northern 
Territory (NT) and to identify any maternal and neonatal risk factors for disease (see Appendix for data 
collection tools).  
The second publication, ‘GBS Case-Control Study’, reports the outcomes of the case control study. A 
primary objective of this study was to determine maternal and neonatal risk factors for GBS neonatal 
infection in the SA and NT between the years 2000 to 2015. A further primary objective is to measure 
the incidence of GBS neonatal infection in SA and the NT for early-onset GBS disease (disease in the 
first 7 days of life) and late-onset GBS disease (disease occurring after 7 days to 90 days of life), as 
well as to comment on the clinical features and burden of GBS disease. The SA incidence of probable 
and confirmed cases of early onset GBS was found to be 32 per 100,000 live births and of late onset 
GBS was 17.8 per 100,000 live births; and NT incidence of early onset GBS was 90 per 100,000 live 
births and 17.8 per 100,000 live births for late onset GBS. 
This information will assist in determining whether a future GBS vaccination program should be 
recommended for pregnant mothers in the future. This large study conducted at five hospital sites, 
required the participation of several site supervisors and data collectors, with Human Research Ethics 
Committees approvals obtained at each site including the SA Aboriginal Human Research Ethics 
Committee approval (see Appendix for Human Research Ethics committee approval forms).
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LITERATURE REVIEW: OVERVIEW OF GROUP B STREPTOCOCCUS SCREENING AND 
NEONATAL GBS DISEASE MANAGEMENT IN AUSTRALIA  
 
1.1 Group B Streptococcus: Pathogenicity & Epidemiology 
Group B streptococcus (GBS) Streptococcus agalactiae is responsible for the majority of serious neonatal 
infections. (1, 2) Neonatal group B streptococcus infections are categorised as early-onset GBS (EOGBS) 
disease, occurring in the first week of life, or late-onset GBS (LOGBS) disease, occurring after the first 
week until 90 days of life. (2) EOGBS infection is the result of transfer of GBS bacterium from the mother’s 
colonised genital tract to the fetus. (3)  During delivery vertical transmission of GBS from mother to infants 
can occur in 30–70% of cases. (4) The pathogenesis of late-onset infections is less clearly defined and 
likely multifactorial. (5) GBS pathogens can be acquired during delivery via the birth canal, but nosocomial 
and other maternal factors, such as GBS being passed to the infant via breast milk, are likely to be 
involved. (5)  
 
In the 1970s GBS emerged as the principal pathogen responsible for neonatal sepsis. (6-8)  Isolates of 
GBS can be divided into 10 capsular polysaccharide (CPS) serotypes (Ia, Ib, II - VIII, IX) which are 
each antigenically individual with serotype III being a major cause of neonatal disease, in particular 
GBS meningitis (9). Further studies have also shown that on a molecular level, using GBS multi-locus 
sequence typing, the GBS capsular serotype clonal complex 17 (ST-17), also appears to be a key 
serotype causing neonatal disease. (10) 
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1.2 Group B Streptococcus Infections: Risk factors & Clinical Disease 
Identified maternal and neonatal risk factors for GBS disease include: “prematurity, maternal group B 
streptococcus carriage, prolonged rupture of membranes (greater than 18 hours), and signs of maternal 
chorioamnionitis such as maternal intrapartum fever”. (11) Neonates with EOGBS and LOGBS present 
with a wide range of clinical symptoms ranging from “respiratory distress, oxygen requirement, 
hypothermia, hyperthermia, lethargy, poor perfusion, hypotension and seizures”. (12) The effectiveness 
of intrapartum antibiotic prophylaxis (IAP) to mothers in labour to prevent neonatal GBS disease was 
first described in the 1980s (7, 8, 11) and confirmed in a meta-analysis of five randomized trials. (8, 13) 
Administration of IAP during labour has proven to significantly reduce neonatal GBS disease. (11)  Prior 
to screening protocols and IAP, the incidence of EOGBS disease in Australia was reportedly 2-3 per 
1000 live births. (12, 14) The subsequent introduction of IAP into many countries’ neonatal GBS screening 
protocols has led to a reduction in the incidence neonatal GBS disease by 50% - 80%. (8, 15, 16) Prior to 
the implementation of maternal IAP, the incidence of EOGBS was considerably higher than LOGBS, 
responsible for ‘approximately 80% of neonatal GBS infections.’ (17) Since the introduction of IAP into 
GBS prevention strategies, both syndromes are approaching similar rates in Australia. (17, 18) 
 
1.3 Group B Streptococcus Infections: Risk-based vs Universal Screening Approaches 
Two major screening approaches have been adopted internationally. The first is based on stratification 
of risk for pregnant women at the time of delivery with IAP administered to women in labour with clinical 
risk factors for the disease. (2) The second is based on the universal screening of pregnant women by 
vaginal and rectal swabs for GBS with IAP then offered to carriers.(2) Internationally it is recommended 
that screening for GBS is conducted via a rectal and vaginal swab for GBS detection at 34–37 weeks’ 
gestation, (12)  with the ‘positive predictive value of GBS culture within this period of 87% and negative 
predictive value of 96%’. (12, 19) IAP is also offered to women if there are risk factors for GBS disease, 
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such as “a mother having a previous infant with invasive GBS disease, GBS bacteriuria in the current 
pregnancy, a positive GBS screening culture during the current pregnancy, prematurity, any suggestion 
of chorioamnionitis such as an intrapartum temperature (regardless of GBS status), and prolonged 
ruptured membrane of > 18 h where GBS status is unknown”. (12)  While a screening-based approach 
has not been reported to change IAP use when compared to a risk-based approach, (12, 20) screening for 
GBS by culture rather than by assessing risk factors may significantly reduce antibiotic usage. (12, 21) 
The United Kingdom and the Netherlands have adopted a risk-based approach alone, (22-24) which is 
likely related to the concern of widespread maternal IAP usage. The major concerns regarding the use 
of maternal IAP for GBS screening protocols is that it ‘will lead to greater chance of selecting for non-
GBS and more resistant organisms creating antibiotic resistance in particular organisms’ causing 
EOGBS and other serious neonatal infections. (12, 16)   
 
1.4 Group B Streptococcus Infections: Impact on Screening Approaches 
The data on the impact of screening on the incidence of GBS disease is similarly conflicting. An 
Australian study reported a fall in the incidence of EOGBS from 0.84 per 1000 live births during the pre-
screening period to a significant 0.00 per 1000 live births after the institution of GBS screening. (12) As a 
result, the authors calculated that ‘in order to prevent one case of EOGBS, 1191 colonised women 
would be required to be given IAP’. (12) Furthermore, they concluded that ‘since maternal colonisation 
incidences of GBS are 24% and the positive predictive accuracy of antenatal culture-based screening is 
87% (19)  5704 women would need to be screened to prevent one case of EOGBS’. (12)  Similarly, after 
GBS screening guideline introduction in the United States of America (USA), which comprised a 
universal screening approach to GBS using rectovaginal swabs, there was a decrease of early onset 
GBS sepsis and meningitis from 1.7 per 1000 livebirths to 0.6 per 1000 livebirths in (between 1990 to 
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1998); (16, 25) and after widespread introduction of universal screening in 2002 in the USA, the incidence 
of early-onset disease fell further, from 0.47 per 1000 livebirth to 0.34 per 1000 livebirths. (25) 
 
However, a study conducted in the Netherlands showed that the introduction of GBS screening (using 
the risk-factor based approach) and treatment guidelines for invasive group B streptococcus disease in 
1999 ‘did not reduce the incidence of disease in neonates in the following 25 years’. (2). In fact, there 
was an increase in the incidence of invasive GBS infection from 0.20 per 1000 livebirths to 0.32 per 
1000 livebirths in 2011 (p<0·0001), and increased incidence of EOGBS from 0.11 per 1000 livebirths to 
0.19 per 1000 livebirths (p<0·0001) between 1987 and 2011. (2) This was attributed to a rise in the 
number of cases caused by GBS belonging to a specific GBS serotype III ( clonal complex 17) and a 
decrease in a specific GBS serotype III ( clonal complex 19), resulting in largely the same distribution of 
GBS serotype III before and after the introduction of IAP. (2). The authors postulated that the rise in 
incidence may be due to “changes in the host, medical practice, increased submission of isolates to the 
National Laboratory, or the pathogen itself”. (2). 
 
Similarly, an epidemiological study from England and Wales spanning 20 years between 1991 and 
2010, showed a steady increase for GBS from 0.42 per 1000 live births to 0.70 per 1000 live births, 
largely accounted for by marked increases in late-onset disease, from 0.11 per 1000 live births to 0.29 
per 1000 live births, (26)  following introduction of guidelines in 2003 using the risk factor approach. This 
steady increase was thought to be related increased numbers of premature infants, (26) but the authors 
determined that they may not have captured the true levels of EOGBS treated by IAP, as only culture 
proven GBS was included in this study. (26) 
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In Australia, the approaches used include both the universal screening with swabs and risk-based 
approach, and may explain why we have seen a decrease in EOGBS in Australia, like the USA which 
adopted the universal screening approach. Unlike the USA and many European countries, the 
Netherlands and the UK have only adopted the risk-based screening approach (22-24) which may explain 
the steady incline of EOGBS in these countries.  Worldwide there appears to be ongoing contradictory 
data regarding GBS incidence and burden, and only by knowing the true incidence of EOGBS, LOGBS 
and disease burden in Australia will we be able to make informed public health choices regarding a 
future GBS immunisation program, which has the potential to ameliorate the disease.  
 
1.5 Group B Streptococcus Infections: Current knowledge gaps 
This study will provide important data on the true incidence of the disease, as well the exploration of 
potential risk factors for disease and incidence, for example ethnicity and whether it is an additional risk 
factors for disease or disease mortality. This data will help inform whether a future GBS vaccination 
program for pregnant women would be beneficial. For instance, studies conducted in the USA have 
shown black ethnicity groups have a higher incidence of GBS, (27) however in Australia we do not have 
conclusive evidence to say whether individuals of Aboriginal or Torres Strait Islander (ATSI) ethnicity is 
an independent risk factor for maternal GBS colonisation or neonatal GBS disease. One study 
conducted in 1995 showed that Aboriginal Australian infants have a rate three times higher of GBS than 
non-Aboriginal infants (5.2 per 1000 births vs 1.7 per 1000 infants), (14) however more recent data did 
not find that Aboriginal newborns were more at risk of neonatal sepsis. (28) The discrepancies between 
these two studies is further evidence that the true disease burden and risk factors for EOGBS and 
LOGBS in Australia remains unknown, and further evidence is required to ascertain the true disease 
incidence and burden. Only then will we be able to develop and implement a vaccination program to 
target certain population groups if they are shown to be at greater risk for disease.
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1.6 Evaluation of South Australian Perinatal Practice Guidelines GBS Screening Practices & Why 
Further Studies Are Required 
 
South Australia (SA) has had formal guidelines for the management of GBS colonisation in pregnant 
mothers at 36 weeks with a low vaginal swab and treatment of neonatal GBS disease since 2004, (29) 
following a publication by the Centre for Disease Control (CDC) for a consensus approach to GBS 
screening and maternal IAP in 2002. (30)  It is recommended that IAP for GBS should be “given as soon 
as possible in labour” with adequate GBS prophylaxis considered to have been achieved if at least “1 
dose of antibiotics is given 4 hours before birth”. (29)  There has been ongoing debate as to whether 
antibiotics given less than 4 hours before birth will confer some benefit to the neonate. While some 
studies suggest that administration as little as 1-2 hours before delivery may offer some protection, this 
is not as effective in preventing EOGBS as maternal antibiotic administration 4 or more hours prior to 
birth. (31) In reality, these guidelines are followed to the treating clinician’s discretion, and there is 
currently no available data from any auditing process in SA regarding the true incidence of GBS 
neonatal disease or if mothers received antibiotics and how soon before delivery this occurred.  
 
The SA perinatal guidelines suggest that infants are deemed to be at risk for early onset neonatal GBS 
sepsis if there are any of the following: ‘evidence of maternal chorioamnionitis (maternal temperature 
above 38° C, maternal pulse > 100/min, fetal heart rate > 160 bpm, uterine tenderness, rising CRP or 
white blood cell count, unless there is another obvious cause), preterm labour at less than 37 weeks 
gestation, preterm or pre-labour rupture of membranes, and prolonged rupture of membranes greater 
than 18 hours at term (greater than 36 weeks gestation) with or without labour.’ (29) An infant is also 
considered high risk if the mother is GBS positive, defined as: ‘maternal GBS vaginal colonisation 
during this pregnancy based on a swab taken less than 5 weeks before labour, maternal GBS 
bacteriuria in the current pregnancy, and early-onset neonatal GBS sepsis in a previous pregnancy’. (29) 
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There is no current data on which of the presenting clinical features are the most accurate predictors for 
the risk of vertical transmission of GBS from mother to infant. Further data collection is required to 
determine the true risk factors for GBS disease in our Australian population and any new risk factors for 
EOGBS and LOGBS disease.  
 
Over time there has been variation in the clinical guidelines with respect to the type of investigations 
ordered on the mother and infant. With regards to maternal investigations, compared to earlier 
iterations of the clinical guideline, the updated version published in 2009 placed greater emphasis on 
not solely relying on a negative maternal GBS swab as a reliable indicator as reduced risk. (32) This was 
based on data from a retrospective cohort study of 61% of term infants with EOGBS where the 
antenatal maternal screening GBS swab was used as a guide to GBS status at birth was falsely 
negative. (33) In addition, maternal GBS bacteriuria, demonstrated in the current pregnancy, and the 
mother having a previous infant infected with GBS was also recognised as increasing the risk of 
neonatal GBS infection. (32) Interestingly the 2009 guidelines reiterated the importance of recto-vaginal 
swab sampling, as opposed to low vaginal alone, which resulted in an increase in the detection of 
maternal GBS carriage from 22% to 27%.  (32)  A 22% detection rate of maternal GBS colonisation 
seems low when considering it is the basis for screening all women during pregnancy.  Therefore, the 
determination of the true percentage of maternal GBS colonisation, how it was detected (rectovaginal 
vs vaginal only) and what percentage of these women then have an infant with proven neonatal GBS 
disease are all critical in refining the clinical management of this patient group. 
 
Since 2007 the guidelines have recommended that neonates displaying signs of sepsis or with whom 
had mothers with maternal chorioamnionitis, should have a blood culture, complete blood picture and a 
band (immature neutrophils)/total neutrophil ratio. (34) In addition, the neonate should receive antibiotics 
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and a lumbar puncture, an endotracheal aspirate, gastric aspirate and surface swabs to determine 
colonisation of flora soon after a birth (however the 2004 guidelines did note that this had a poor 
correlation with invasive sepsis). (29) Previously utilised neonatal urine latex tests are a poor screening 
test for assessing suspected sepsis in newborns, (34) and as a result are no longer routinely conducted 
in the workup of infants.  
 
The 2012 guidelines stipulated that normal ranges for neonatal complete blood pictures ‘vary with 
population, gestation and postnatal age,’ (35, 36) and that the band (immature neutrophils): total 
neutrophil ratio was the most sensitive indicator of sepsis (37) with a band neutrophil ratio (or [I/T] ratio) 
of > 0.2 a suggested cut-off for treatment for the neonate with antibiotics. (38)  However, the blood 
picture may be normal if taken too early after birth in a colonised baby and sensitivity increases at 4-6 
hours after birth. (39) There has been no data since the implementation of these guidelines in SA to 
corroborate how many infants with EOGBS and LOGBS are demonstrating a total [I/T] of > 0.2 and 
whether this is the sole factor in the treating clinicians’ decision to administer antibiotics. Owing to the 
‘high false positive rate of the blood picture’ in asymptomatic term babies at risk of sepsis, (39) antibiotics 
are often given until blood cultures are negative at 24 hours, and the complete blood picture has 
normalised. (39) Therefore, this study will collect data on what percentage of asymptomatic infants with 
risk factors are receiving these antibiotics, compared to ‘population, gestation and postnatal age’ of 
infants with true disease. This data will help inform if these infants are truly at a risk for EOGBS and 
LOGBS and may result in rationalisation of antibiotic usage. In turn, this may potentially decrease the 
economic burden of unnecessary antibiotic usage and associated prolonged hospital stay. 
 
Currently, term asymptomatic infants whose mothers are GBS positive, or GBS unknown with ROM > 
18 hours with incomplete IAP, are investigated with a complete blood picture (see appendix for 
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treatment algorithm). However, if an asymptomatic term baby has a negative maternal GBS swab (or is 
GBS unknown with ROM < 18 hours), the guidelines suggest they do not require a full blood count but 
have ‘four hourly respiratory rate and temperature observations for 24 hours.’ (29) Preterm babies that are 
asymptomatic and whose mothers received inadequate IAP should be investigated and treated with 
antibiotics. (29) If these mothers received adequate IAP, these newborns are investigated but ‘antibiotics 
are given selectively based on results of preterm cultures or degree of prematurity.’ (29) This study will 
collect data on neonatal investigations on premature or asymptomatic term infants with positive 
maternal GBS swabs, or prolonged rupture of membranes, and relate this data to subsequent 
development of EOGBS or LOGBS. In addition to determining the compliance to current guideline 
recommendations, this data may support rationalisation of maternal IAP use. 
 
There is no doubt that one consequence of following these clinical guidelines may be a prolongation of 
hospital stay for some infants. Previous SA guidelines (2009 – 2011) stated that infants with risk factors 
for sepsis should be observed in hospital for at least 24 hours (in the discussion of early discharge 
home < 48 hours after birth of the term asymptomatic infant with risk factors), with a caveat that some 
individual circumstances may indicate a longer period of observation. (32, 40, 41)  In 2012 the 
recommendation was made that “term asymptomatic babies at risk for sepsis but with adequate 
intrapartum antibiotic prophylaxis, and those where mother is GBS unknown but with no other risk 
factors, may be discharged after a minimum observation period of 4-6 hours. If discharged, parents 
should be advised to seek immediate medical attention is their baby develops breathing difficulty or 
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1.7 Routine GBS screening and treatment with IAP vs future vaccination programs 
Both the universal screening approach and the assessment of maternal risk factors approaches have 
advantages and disadvantages, for example, the former being more expensive (12). The latter approach 
is ‘easier to implement, but difficult to monitor because there is no specimen collection, processing and 
reporting of results.’ (8, 12) It has been demonstrated that the screening-based approach was almost 
‘50% more effective in preventing early-onset GBS disease (0.33 per 1000 vs 0.59 per 1000 live 
births)’. (20) The study stated that ‘risk factors were present in 24% of women and the use of antibiotics 
was similar in both groups including the screened group and unscreened group (31% and 29% 
respectively), demonstrating that the screening-based approach did not result in significant increase in 
antibiotics usage’. (12, 20) Australia currently employs both the risk based and screening-based 
approach. 
 
A Cochrane review on the topic evaluated three trials (capturing 500 women) assessing the effects of 
maternal antibiotic prophylaxis versus no treatment.  The review showed that IAP did ‘not significantly 
reduce the incidence of all-cause mortality, mortality from GBS infection or from infections caused by 
bacteria other than GBS’. (40) The incidence of early GBS infection was reduced with IAP compared to 
no treatment [risk ratio (RR) 0.17, 95% confidence interval (CI) (0.04 to 0.74)] with a calculated number 
needed to treat to of 25.(40)  However,  the ‘incidence of LOGBS was not significantly different between 
groups’, (40) with the authors proposing that ‘giving antibiotics was not supported by conclusive 
evidence’. (40) Importantly, the authors concluded that even though IAP appeared to reduce EOGBS, 
this result was at high risk of bias due to the included studies’ methodology and execution which did not 
include preset sample sizes, the lack of a placebo in the control groups, and the exclusion of women 
who developed signs of infection in labour. (40)  
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This systematic review also reiterated that little data has been collected in North America following the 
implementation of GBS screening guidelines and IAP, and that there were only three randomised 
controlled trials conducted more than 20 years ago in three different countries that have been 
published, encompassing a total of 500 women. (40) Similarly in Australia, there is also a sparsity of data 
on GBS, highlighting the importance of further data collection to elucidate the true disease incidence 
and burden, in order to address EOGBS and LOGBS effectively in our local and global community.  
 
1.8 Future GBS vaccination programs 
With the lack of conclusive evidence supporting IAP and cost of universal screening, it appears that the 
future management of this disease lies in prevention with a maternal vaccine in pregnancy as opposed 
to treatment with maternal IAP and neonatal antibiotics. Given the significant morbidity and mortality 
that GBS causes in our infant population worldwide, such a vaccination program may finally be the 
answer to decrease the stable incidence of LOGBS, which IAP has not been able to do, and potentially 
eradicate the disease altogether. There are several advantages to such an immunisation program. 
Maternal immunisation would be more cost effective than IAP, does not need to be administered during 
each pregnancy, it would eliminate the concern regarding ‘development of antimicrobial resistance in 
GBS with maternal IAP, and most importantly, it has the potential to prevent LOGBS’. (41) Immunisation 
would offer several advantages over maternal IAP as maternal IAP is not without its own risk and would 
be an acceptable approach to disease prevention in Australia, where maternal vaccination programs for 
pertussis and influenza to confer immunity to the fetus already exist. IAP given to pregnant women is 
not without risk as they can cause allergic reactions in the mother, which can be severe and potentially 
life-threatening.  Maternal IAP can also increase the possibility of resistant strains of GBS, and 
concerningly it is reported that ‘20% of GBS isolates are already resistant to clindamycin and 30–40% 
to erythromycin’. (42, 43) 
 
  
GBS STUDY| LITERATURE REVIEW: GBS VACCINATION PROGRAMS  19 
 
Developing an appropriate vaccine requires an understanding of the main virulence factors associated 
with GBS. GBS is a gram-positive encapsulated coccus which occurs in pairs or short chains which 
shares a common Lancefield group B polysaccharide antigen. It is further distinguished on the basis of 
type-specific CPS into ten antigenically unique serotypes (Ia, Ib, II-IX).’ (4, 44) In past decades it has been 
proposed that ‘95% of infant and maternal GBS disease is caused by only five capsular polysaccharide 
serotypes: Ia, Ib, II, III and V’, (45, 46) and for serotypes Ia, Ib, III and V, and several studies indicate that 
protective human immunity is associated with sufficient amounts of maternal antibodies to these 
capsular polysaccharides’. (47) GBS virulence factors include the use of capsular polysaccharide (CPS), 
adhesion factors that increase binding to host cells, inducing pore-forming toxins into host cells which 
cause damage, evasion factors which prevent complement binding and lead to a decrease in 
recruitment of neutrophils, and repelling and resisting antimicrobial peptides. (48) CPS is the ‘most 
widely studied GBS virulence factor as it acts by facilitating evasion of the host’s immune system on a 
molecular level’, (49) and it has been suggested that there is a ‘correlation between invasive neonatal 
GBS infection and low levels of maternal antibodies to CPS antigens’. (4, 50)  
 
CPS has emerged as a popular vaccination target in the last decade as a result of its importance as a 
virulence factor. (51)  A study by Baker et al demonstrated that high ‘maternal antibodies correlate with 
protection against serious GBS infection in neonates and that vaccination of pregnant women against 
CPS might be an effective strategy to protect neonates against GBS infection’. (4, 50) This may be 
incredibly important for premature infants, as they only possess approximately 30-50% of maternal 
antibody compared to term infants. Mothers at risk of having premature labour would be good 
candidates for a GBS vaccine to provide ‘higher antibody levels that can compensate for prematurity 
and potentially protect their infants from late-onset disease’. (52) 
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GBS vaccine development has only advanced to phase 1b/II trials by vaccine manufacturer 
Novartis/GSK (53), which is a trivalent (Ia, Ib, and III) GBS polysaccharide conjugate vaccine. (54) In 2017 
the vaccine manufacturer Pfizer started phase 1 trials to assess a pentavalent GBS polysaccharide 
targeting GBS serotypes Ia, Ib, II, III, and V. (55) Vaccination to target GBS disease prevention would 
revolutionise the treatment and management of this disease, and not only would it finally lead to 
decreasing levels of late onset GBS disease (which the advent of IAP has not been able to achieve), 
but it would also decrease the rates of miscarriage and stillbirth related to overwhelming GBS infection. 
(44)
 
1.9 Summary of current concerns regarding neonatal GBS and the need for this study 
There is currently no mandatory reporting for neonatal GBS infection or its complications in Australia, 
and previous reported incidences of early onset and late onset GBS disease has come from studies 
now over 10 years old and have relied on passively reported data from clinicians to the Australian 
Paediatric Surveillance Unit. As a result, we do not know the true incidence of early onset and late 
onset infection in SA or the NT. There is also concern regarding the use of intrapartum antibiotic usage 
in the management of mothers found to be at high risk for an infant with neonatal GBS disease. This 
study will ascertain if there are any new risk factors for neonatal GBS infection and identify the true 
incidence of the disease in SA and NT. Gathering this data will be imperative in deciding on a feasibility 
for a future perinatal GBS vaccination program in Australia in order to potentially eradicate this 
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ABSTRACT 
Introduction  
Group B streptococcus (GBS) is the most common cause of life-threatening infections in the neonatal period 
and the leading infectious cause of morbidity and mortality in newborns. The GBS bacterium colonises 
approximately 10% to 30% of pregnant women. Understanding the incidence, risk factors and outcomes of 
neonatal GBS will help inform hospital guidelines in the appropriate use of intrapartum antibiotic prophylaxis 
(IAP). It will also inform use and the potential for the introduction of a GBS vaccine program in Australia for 
pregnant women to prevent further neonatal morbidity and mortality. 
Methods and analysis 
Cases of neonatal GBS disease will be identified by laboratory database searches for positive GBS cultures 
and medical record clinical auditing using international statistical classifications of disease (ICD 10) code P 
36.0 (sepsis of the newborn due to group B streptococcus). A 16-year period from 2000-2015 in South 
Australia (SA) and Northern Territory (NT) will be reviewed. Cases will be distinguished into early onset GBS 
disease (<7 days) and late onset GBS disease (≥7 days to 90 days).  
Two control cases will be selected for each index GBS case. These will be the first baby born before and after 
the index GBS case, falling within in a similar weight category and matched for sex. The control infants will 
be excluded if they have evidence of sepsis during the first 90 days of life. 
Risk factors for GBS neonatal infection in SA and NT will be collected using a data collection tool and 
determined via a case control design and multivariable logistic regression analysis. 
Ethics and dissemination 
This study was approved by all institutional Human Research Ethics Committees responsible for participating 
sites. Additional ethics approval was applied for and granted by the Aboriginal Health Research Ethics 
Committee in South Australia. Study findings will be published in peer review journals and presented at 







Strengths and limitations of this study: 
 
• This study will provide generalizable data on risk factors for early and late onset GBS for 
Australian mothers and infants with data collected from three hospitals in South Australia and 
two hospitals in the Northern Territory, Australia over a 16-year study period. 
 
• This study will provide an accurate incidence of Group B streptococcal infection in Australian 
infants <90 days of age. 
 
• Both clinician-diagnosed and laboratory-confirmed cases will be included and hospitalisation 
data and laboratory data cross-matched to ensure complete ascertainment of cases. 
 
• A limitation of this study includes clinician bias when interpreting whether infants had clinical 
signs of GBS disease in the absence of laboratory confirmation, ‘probable cases’ of GBS 
disease were included in this study but were not included in the statistical analysis when 
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INTRODUCTION 
Group B Streptococcus (GBS) is a bacterium that commonly colonises the gastrointestinal tract and 
vagina of adult women, the urethra of adult men, and the upper respiratory tract of young infants.(56) 
Approximately 10% to 30% of pregnant women are colonised with GBS.(57) When newborns are exposed 
to GBS it can cause sepsis and meningitis. Neonatal and infant GBS infections are categorised according 
to age at onset of infection. Early onset disease refers to disease occurring during the first week of life (0 
to 6 days), frequently presents as sepsis or pneumonia and is usually due to exposure to GBS before or 
during the birth process. Late onset disease applies to infants with disease from 7 to 90 days post birth, 
often presenting as bacteraemia and/or meningitis and may reflect vertical transmission or transmission 
from community or nosocomial sources.(58)  
Infants who develop neonatal sepsis may be at risk of neurodevelopmental impairment, although there 
is limited information regarding the long-term outcome for survivors of GBS bacteraemia or sepsis.(59) 
Those with neonatal sepsis who are born premature, or of low birth weight, are likely to be at even greater 
risk of adverse neurodevelopmental sequelae.(60-65)  
Pro-inflammatory cytokines in amniotic fluid and in foetal or neonatal blood appear to increase the risk 
for neonatal brain injury and adverse long-term outcome, with experimental data indicating that 
inflammatory cytokines may be neurotoxic and can increase the permeability of the preterm blood brain 
barrier (63).  Neonates with infection are also at risk for circulatory and respiratory insufficiency with 
decreased systemic blood pressure, hypoxemia, and pathologic alterations in cerebral blood flow, which 
also contributes to adverse neurodevelopmental sequelae.(63)  
Accurately characterising the outcomes of serious infections is a crucial component of disease 
surveillance. Much of the information on outcomes for survivors of neonatal GBS infection is based on 
children who survived GBS meningitis prior to 1980. Of those children 25% to 50% had permanent 
neurologic sequelae including profound intellectual disability, quadriplegia, cortical blindness, deafness, 
uncontrolled seizures, and hypothalamic dysfunction.(66-72) More recent studies conducted in the USA 
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and UK suggest that there has been little improvement in outcomes for children with neonatal GBS 
meningitis.(73-75) No similar studies have been conducted in Australia.  
At present, neonatal GBS sepsis and meningitis is not a notifiable disease and there are sparse data on 
disease incidence in Australian infants. In addition, data on GBS affecting Aboriginal and Torres Strait 
Islander infants (ATSI) is similarly limited.(28, 76, 77) The identification of risk factors for neonatal GBS 
disease is critical for an understudied Australian population. 
Currently there are two main strategies used in Australia and internationally to try and reduce the 
incidence and severity of neonatal sepsis and meningitis; routine GBS screening of all women (vaginal 
and rectal swab) as well as risk-based assessment versus risk based GBS assessment only.  However, 
there is currently no consensus on which should be routinely applied, and critically, both approaches are 
supported by low quality evidence.(58, 78)  
In SA and the NT, public hospital guidelines recommend all pregnant women between 35-37 weeks’ 
gestation be screened using a recto-vaginal swab for GBS culture. If women are found to be colonised, 
they are offered IAP treatment. Women who return a negative swab for GBS but who have a complication 
during pregnancy/labour such as premature rupture of membrane are also offered IAP.  
However, in many countries and other jurisdictions in Australia, routine screening with recto-vaginal swab 
for GBS culture is not performed and only a risk-based strategy is used. This approach is also preferred 
by 44% of Australian neonatologists.(17, 79) Infants at greatest risk of EOGBS sepsis are those born to 
women who experience preterm labour or delivery, have membrane rupture greater than 18 hours prior 
to delivery, intrapartum maternal fever or maternal chorioamnionitis, or a previous delivery of an infant 
with GBS disease.(17) The risk-based method has been shown to be less effective at reducing GBS 
infections in newborns compared to the universal screening method, but is more cost effective with 
significantly lower rates of antibiotic administration.(17) Importantly, it has been reported in settings using 
an antenatal screening approach that approximately 60% of EOGBS cases occur among women with 
negative GBS cultures at antenatal screening, highlighting an inherent limitation with screening and
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 IAP.(33) Further, maternal IAP does not reduce the incidence of late-onset disease.(51) Similarly, not all 
cases of EOGBS are identified using a risk based approach, a recent study in the UK showed that the 
majority of babies with EOGBS do not have risk factors evident at delivery so will be missed by such a 
strategy, with only 35% of EOGBS cases had 1 or more risk factors antenatally.(80) 
 
Current Surveillance within Australia  
In 2012 a systematic review only identified three studies investigating the incidence of neonatal GBS 
infection in Australia.(81) Each study confirmed that since the introduction of intrapartum antibiotics, the 
incidence of early onset neonatal GBS has fallen.(12, 82, 83) However, all reported data are now over a 
decade old. One of the studies conducted over a 10-year period in Australia and New Zealand reported 
that the incidence of early onset neonatal GBS sepsis had dropped from 143 per 100 000 in 1993 to 25 
per 100 000 live births in 2001.(82) A slight decrease was reported in late onset GBS disease incidence 
with 94 per 100 000 prior to the introduction of IAP and 72 cases per 100 000 after its introduction.(12) 
A more recent prospective surveillance study by the Australian Paediatric Surveillance Unit (APSU), 
published in 2015, identified GBS disease in infants aged 0–90 days between July 2005 and June 2008 
at 12 major public hospitals across Australia (the NT was not included in this study).(84)  Despite a reporting 
rate of one-third of that of known GBS cases to the APSU in this time, indicating the limitations of relying 
on passively reported data and not laboratory confirmed cases, the authors estimated rates of EOGBS 
to be 38 cases per 100,000, and LOGBS 19 cases per 100,000 live births.(84)   
In comparison, a retrospective study conducted in Townsville, Queensland (QLD) estimated the 
incidence of EOGBS as 43 per 100,000 live births and 38 per 100,000 for LOGBS, (77) with LOGBS 
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Burden of GBS in Aboriginal and Torres Strait Islander population 
Minimal research has been conducted in Australia to identify the burden and risk factors for GBS disease 
in the Aboriginal and Torres Strait Islander population. A 2011 study conducted in Townsville, QLD did 
not find that Aboriginal newborns were more at risk of neonatal sepsis, despite this being a finding in 
previous studies.(28) The study also identified risk factors not currently used as part of IAP strategies, 
such as previous foetal loss.(77) Indigenous status was not found to be a risk factor for GBS sepsis in the 
limited study conducted by the APSU.(84) 
 
Impact of antibiotics in the perinatal period on health outcomes  
The long-term impacts of intrapartum antibiotic administration on antibiotic resistance and on intestinal 
flora is currently not clear.(17) It is becoming evident that microbiota colonisation during the neonatal period 
influences adult health.(85) Medical interventions and antibiotics administered during this period that 
disturb microbial colonisation may therefore increase the risk of coeliac disease, atopy, type 1 diabetes, 
obesity and asthma.(85) Some authors have suggested that increased administration of antibiotics due to 
GBS screening may also increase the incidence of neonatal infections caused by pathogens other than 
GBS, including β- lactam-resistant strains.(86)  
 
New GBS vaccines for pregnant women  
The introduction of a GBS vaccine for pregnant women is a key development for the prevention of 
neonatal GBS infection. Advantages of a vaccine include potential eradication of early onset GBS sepsis, 
reduction in the use of antibiotics, prevention of late onset GBS, and a reduction in the costs of screening. 
There may also be an additional impact on endpoints for which the association with GBS is less clear, 
such as stillbirths and prematurity. A study in the UK showed that a GBS vaccination program would 
prevent about twice as many cases of death and disability in the neonate as microbiological screening, 
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and three times as many as risk factor-based screening.(87) A recent study in the UK has shown that such 
a maternal vaccination program would be cost effective against neonatal invasive GBS.(88) Several 
different GBS antigens have been considered for inclusion in potential vaccines.(89) A trivalent 
polysaccharide conjugate vaccine has been studied in pregnant women with efficient transplacental 
antibody transfer to the foetus and persistence of antibody until 2 months of age.(90) One concern with 
the development of a globally effective vaccine is the existence of up to 10 GBS serotypes capable of 
causing disease, with different geographical distributions around the world. Currently, phase I studies 
using hexavalent GBS vaccine have been started (evaluating serotypes Ia, Ib, II, III, IV, and V) in non-
pregnant women, which will likely proceed into phase Ib/II studies in pregnant women by 2020.(91) 
 
Rationale and objectives for proposed study 
The objectives for this study are to determine the risk factors for neonatal GBS in an Australian population, 
and to determine the true incidence of early onset and late onset GBS in SA and the NT. Knowing the 
true incidence, and whether certain populations pose a higher risk for EOGBS and LOGBS, will provide 
critical information necessary to assess the feasibility of a GBS vaccine program in Australia. This study 
phase will consist of a descriptive study that identifies GBS infections in infants less than 90 days old 
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METHODS AND ANALYSIS 
Study Design 
The SA and NT pathology databases will be searched for GBS positive sterile site specimens from infants 
aged less than 90 days at time of diagnosis as well as using the “ICD 10 CODE P36.0” (Sepsis of newborn 
due to streptococcus, group B). Once potential cases have been identified a case note audit will be 
conducted to confirm or exclude cases.  Cases will be classified using an adapted case definition from 
the Ontario Public Health Standards Infectious Disease Protocol case definition in which a “confirmed 
GBS case” will be an infant less than 90 days of age in whom GBS has been cultured from a normally 
sterile site, together with clinically compatible signs and symptoms of invasive disease.(40) Clinical 
presentations of GBS disease are characterised by an infant having either: (1) Early onset disease (<7 
days), usually characterised by sepsis, pneumonia, meningitis, osteomyelitis or septic arthritis OR (2) 
Late onset disease (≥7 days to 90 days), usually characterised by sepsis and meningitis.  
 
A “probable GBS case”, i.e. a clinically suspected case, will be that of an infant with clinically compatible 
signs and symptoms with a diagnosis of neonatal GBS disease in a newborn up to 90 days after birth, 
whose mother has laboratory confirmation of Group B streptococcus from a lower vaginal or anorectal 
specimen. Probable GBS cases will be included in the study to determine the incidence of GBS disease 
and to ensure completeness of reporting in cases where an infant is treated early with antibiotics before 
all the appropriate specimens have been taken, however these cases will not be included in the statistical 
analysis of this study when determining risk factors for neonatal GBS disease.  
 
Both cases and controls will be identified at the Women’s and Children’s Hospital, the Lyell McEwin 
Hospital, Flinders Medical Centre in SA and the Royal Darwin Hospital and Alice Springs Hospital, NT. 
Two controls per case will be selected using the hospital birth register, one control will be an infant born 
as soon as possible before the case and the other control as soon as possible after the case, where both 
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infants are the same sex and fall in the same birth weight category as the case (categories: <749 g, 750–
999 g, 1000–1499 g, 1500– 1999 g, 2000–2499 g, 2500–2999 g, 3000–3499 g, >3500 g). The control 
infants must have no evidence of clinical infection requiring IV antibiotics during the first 90 days of life, 
which was ascertained during medical case note and pathology database audit.  
 
To determine risk factors, a standardised data collection tool will be used to obtain clinical information 
from GBS cases and control mothers and neonates including (but not limited to):  age, sex, indigenous 
status and geographical distribution; disease type (i.e. meningitis, pneumonia or septicaemia); disease 
symptoms & date of onset; date of admission & date of discharge; level of admission, and length of time 
at each level i.e. ICU/HDU/general medical ward; results of investigations performed; outcomes and
 identified sequelae; clinical interventions; screening (maternal risk assessment, type of swab or culture, 
and antibiotic administration); and clinical information (parity, gestation, membrane rupture greater than 
18 hours prior to delivery, intrapartum maternal fever, suspicion of chorioamnionitis, GBS colonisation, 
birth weight, mode of delivery, APGAR scores, whether resuscitation was performed, history of previous 
fetal death (in this study defined as death during any gestation during pregnancy), or previous delivery of 




In SA and NT, all the major teaching hospitals will participate to ensure a large proportion of births in 
each region are captured in the search. All infants born between 2000 and 2015 who are identified as 
being GBS positive through hospital coding or laboratory results will be included in the study. Control 
infants born immediately before and after the case in the same sex and weight category will be selected.
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Sample Size and analysis plan 
 
The number of live births identified from the Australian Bureau of Statistics in SA over the study period 
was 303,453 births of which 25,387 births were of Aboriginal or Torres Strait origin (ATSI). The number 
of births in NT over the study period: 61, 628 live births of which 5146 births were of ATSI origin.  Using 
a conservative estimate of cases obtained from rates published by the APSU, which was a rate of 0.11 
per 1,000 births for early onset disease and a rate of 0.08 per 1,000 births for late onset disease, (92) 
approximately 40 early-onset neonatal GBS sepsis cases and 29 late onset GBS cases could be 
expected over the 16-year study selecting this time period. 
 
In 2012 the Women’s and Children’s Hospital, Flinders Medical Centre and Lyell McEwin Hospital made 
up approximately 53% of the births in the state, representing 28%, 19%, and 14% of Aboriginal infant 
births in SA.(93) In the NT the Royal Darwin Hospital and Alice Springs Hospital represent approximately 
67% of the births in NT, with 35% and 55% Aboriginal infant births in NT respectively.(94) 
 
A sample size of approximately 70 cases and 140 controls (1:2 matched design) would provide 100% 
power to detect an odds ratio of 6.88 for maternal GBS carriage,(27) assuming 20% maternal GBS 
carriage.(57) It will provide 98% power to detect an odds ratio of 4.17 for chorioamnionitis,(27) assuming 
10% maternal infection,(95) and 34% power to detect an odds ratio of 1.82 for prolonged rupture of 
membranes(27) assuming this will occur in an average of 12.5% of pregnancies.(95)
 
Potential risk factors will be descriptively summarized among the neonatal GBS disease and GBS cases. 
The association between risk factors and infection will be assessed by logistic regression, controlling for 
matching covariates (weight and sex) and hospital, and expressed as odds ratios with 95% confidence 
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intervals. All potential risk factors will be entered into a multivariable logistic regression, and backward 
selection will be used to determine the final model.  
 
Risk factors and clinical details of GBS early onset and late onset neonatal infection cases will be 
descriptively summarized. To determine risk factors for GBS early onset and late onset neonatal infection, 
potential risk factors will be considered in a multivariable logistic model, controlling for hospital. 
 




ETHICS AND DISSEMINATION 
In SA, ethics approval was granted by the South Australian Aboriginal Health Research Ethics (Reference 
Number 04-16-663) Committee and by the Women’s and Children’s Health Network Human Research 
Ethics Committee (HREC/16/WCHN/025). For the NT, ethics approval was granted by the Central 
Australian Human Research Ethics Committee (HREC-16-388), the Human Research Ethics Committee 
of the Northern Territory Department of Health and Menzies School of Health Research (HREC 
Reference Number 2016-2584). 
 
This study will be conducted according to the Good Clinical Practice Guidelines, and thus consent to 
access medical history will be waived as it is not thought to be appropriate or feasible to obtain participant 
consent as the review extended back to the past 16 years of GBS cases.  A waiver of consent is also 
applicable because the involvement in the research carries no more than low risk to participants, the 
benefits from the research justifies any risks of harm associated with not seeking participant consent, 
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there will be sufficient protection of their privacy and an adequate plan to protect the confidentiality of 
data.  
 
There are no safety concerns identified with this study. Data generated by collection of information from 
medical records and pathology results will be identifiable until the completion of data extraction, for data 
quality assurance (e.g. review and validate the existence of participants in the study, verify their eligibility, 
and ensure the data recorded is accurate and complete). Information collected during the study will be 
entered in an electronic database in a re-identifiable manner. The database will not contain any identifying 
data apart from demographic details. The re-identifiable data is potentially identifiable only at the site 
where a master participant code list will be retained by the investigator. The investigators will analyse the 
collected data in direct relation to the study aims/objectives to determine the outcome of the study. Only 
non-identifiable results will be presented in the final study report or any publications.  
 
The principal investigator will have access to the data and will keep a record of the data held in the 
department. The study documents will be kept as required of any study approved from the participating 
site’s ethics committee and information published from this study will not identify any participants involved 
in this study. 
 
DISCUSSION 
Maternal gastrointestinal and genital tract colonisation with GBS is a significant determinant of GBS 
colonisation and infection in the neonate,(47) with up to 36% of pregnant women known to be colonised.(96) 
Once there is a failure of epithelial barrier function and immunological clearance of GBS, bacteraemia 
can lead to neonatal sepsis or septic shock.(47) In the years before GBS screening and widespread use 
of penicillin, fatal maternal puerperal sepsis due to GBS infection and neonates cultured with GBS at 
autopsy was a relatively common event.(97) Although in many countries IAP has had a significant impact 
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in decreasing the incidence of early-onset GBS disease, it has not reduced the incidence or burden of 
late onset GBS disease.(97) 
 
In some jurisdictions in Australia, routine GBS screening of all pregnant women between 35 and 37 weeks 
gestation includes a vaginal/rectal swab, with the mother offered IAP if the swab is positive. In many 
countries routine swab-based screening is not performed and a risk-based strategy is employed, however 
this method is less effective at reducing GBS infections in newborns.(17)  
 
The most recent Australian study conducted by the APSU in 2015 relied on clinician’s to passively identify 
GBS disease in infants aged 0–90 days between July 2005 and June 2008 at 12 major public hospitals 
across Australia and after comparison with laboratory findings, identified that clinician’s identified less 
than one third of true GBS cases.(84)  Knowing the true incidence of early onset and late onset GBS 
disease in Australia, as well as which groups are at higher risk, will be important to help inform a local 
and national GBS maternal vaccination policy.  
 
Currently Australia has successful pertussis and influenza vaccine programs for pregnant mothers 
whereby vaccination is primarily to protect the infant. (98) Whilst GBS infections rarely cause infection that 
leads to maternal death, it is reported that as high as 60% of infections can result in miscarriage or 
stillbirth of the infant.(49) Neonatal GBS meningitis can cause long term neurological deficits, greater than 
20% of these patients suffer moderate to severe deficits such as learning issues, deafness, global 
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There have been many virulence factors that have been identified with GBS infections for a potential 
vaccine antigen, however the most promising to date is vaccine targeting GBS capsular polysaccharides 
(CPS).(49) Studies have demonstrated that maternal IgG antibodies to CPS correlate with protection 
against invasive neonatal GBS infections.(49) A CPS antigen vaccine would be especially beneficial to 
mothers at high risk for premature deliveries, as premature infants only have 29-51% as much maternal 
antibody as full term neonates.(52) 
 
This study will provide much needed data to identify the true incidence and disease burden of early-onset 
and late-onset neonatal GBS infection in SA and NT, as well as help to identify any risk factors 
predisposing newborns to these infections.  
 
CONCLUSION 
Measuring the incidence, and risk factors of neonatal GBS disease is essential to inform decisions 
about developing interventions to prevent infection or reduce infection rates. It will also help guide local 
and national policy in the appropriate use of intrapartum antibiotics. With the development of a GBS 
vaccine for use during pregnancy, we need to understand the incidence, disease burden, and risk 
factors and outcomes of GBS in infants. Cost-effectiveness estimates for a funded immunisation 
program will be dependent on robust Australian data.
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Table of Contents Summary: Measuring the true incidence of neonatal GBS infection in SA 
and NT will help advice on feasibility of a future maternal GBS vaccination program. 
 
What is known on this subject: Group B Streptococcus infection is a leading cause of 
morbidity and mortality in the neonate. Estimated national incidence is based on old data and 
there is limited data on incidence Aboriginal and Torres Strait Islander infants. 
 
 
What this study adds: This study identifies a new risk factor for GBS, previous fetal death, 
which should be considered in future GBS screening programs. It also reports on the 
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A case control study to assess risk factors for neonatal group B streptococcal infection 
in Australian infants  
Yanni M, Stark M, Francis J, Fearon D, Baird R, Heath P, Macmillan M, Knight E, Gordon 




Objective: To determine maternal and neonatal risk factors and the incidence of neonatal early 
onset (EOGBS) and late onset Group B Streptococcal (LOGBS) infection in South Australia 
(SA) and Northern Territory (NT). 
 
Methods: A case control study design with 2:1 control to cases was used with retrospective 
data collected from a 16-year epoch (2000-2015). Univariate and multivariate analysis was 
used to determine risk factors for neonatal EOGBS and LOGBS. 
 
Results: The SA incidence of probable and confirmed cases of EOGBS was 32 per 100,000 
live births and of LOGBS was 17.8 per 100,000 live births; and NT incidence of EOGBS was 
90 per 100,000 live births and 17.8 per 100,000 live births for LOGBS. When probable cases 
were removed the adjusted SA incidence for EOGBS was 18.1 per 100,000 live births and for 
LOGBS was 17.5 per 100,000 live births, and NT incidence for EOGBS was 35.7 per 100,000 
live births and for LOGBS was 14.6 per 100,000 live births. 
 
Univariate analysis identified the risk factors: maternal GBS carriage, previous baby with GBS, 
previous fetal death, maternal fever in labour/chorioamnionitis, prolonged rupture of 
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membranes > 18 hrs, and mode of delivery. Multivariate analysis identified maternal GBS 
carriage, previous fetal death, and maternal fever in labour/chorioamnionitis as risk factors. 
The strongest risk factors discriminating the likelihood of having LOGBS compared to EOGBS 
was female sex, non-Indigenous status, and low birthweight. 
 
Conclusion:  
The incidence and disease burden of GBS is still significant despite screening programmes and 
maternal intra-partum antibiotics. The implementation of a GBS vaccination program to 




Group B Streptococcus (GBS) colonises approximately 10% to 30% of pregnant women.(17, 57)  
While GBS infections do not lead to maternal death, up to 60% of infections can result in 
miscarriage or stillbirth of the infant.(49) Further, GBS is the most common cause of neonatal 
infections worldwide.(1) Neonatal GBS infection is defined as EOGBS, occurring up to 7 days 
of life, and LOGBS occurring from 7 days to 90 days of life. EOGBS likely develops after 
aspiration of amniotic fluid infected with GBS from the colonised maternal genital tract. (3) The 
pathogenesis of LOGBS is less certain, with nosocomial sources implicated in addition to 
acquisition of the pathogen from the maternal genital tract.(5)   
Prior to the introduction of intrapartum antibiotic prophylaxis  (IAP) for those women at risk 
of GBS disease, the incidence of EOGBS disease in Australia was 200 to 300  per 100,000 live 
births.(14) In SA and the NT, current public hospital guidelines recommend all pregnant women 
between 35-37 weeks’ gestation be screened using a recto-vaginal swab for GBS culture (see 
appendix for treatment algorithm). If found to be colonised, they are offered IAP. However, 
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despite the introduction of routine maternal GBS screening and IAP and a greater than 80% 
reduction in the incidence of EOGBS cases in Australia, GBS still remains a leading infectious 
cause of neonatal morbidity and mortality.(17)  
There is little contemporary data regarding the true incidence of GBS in Australia following 
the introduction of routine maternal screening and IAP. In 2012 a systematic review of the 
global burden of perinatal GBS infection only identified three studies investigating the 
incidence of neonatal group B streptococcal infection in Australia.(81) Each of the identified 
Australian studies confirmed that since the introduction of IAP, the incidence of early onset 
neonatal GBS fell.(12, 82, 83) The largest, multi-centre study reported a reduction in EOGBS 
incidence from 143 per 100,000 live births in 1993 to 25 per 100,000 live births in 2001.(82) 
However, little change was reported in LOGBS disease since the introduction of IAP with 94 
per 100,000 prior to the introduction of IAP and 72 cases per 100,000 after its introduction. (12) 
 
A more recent prospective study by the Australian Paediatric Surveillance Unit (APSU) in 
2015 passively identified GBS disease in infants aged 0–90 days at 12 major public hospitals 
across Australia, notably the NT was not included in this study.(84) Despite clinicians reporting 
only one-third of actual GBS cases to the APSU in this time, indicating the limitations of 
relying on passively reported data and not laboratory confirmed cases, (84) the authors estimated 
rates of EOGBS to be 38 cases per 100,000, and LOGBS 19 cases per 100,000 live births. In 
comparison, a study conducted in Townsville estimated the incidence of early onset GBS as 43
 per 100,000 and 38 per 100,000 for late onset GBS, (77) which was markedly more than national 
figures estimated by the APSU. 
Recently, attention has focused on the potential role for maternal GBS vaccination. 
Internationally, GBS vaccine development has only advanced to phase Ib/II trials,(53) using a 
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trivalent GBS polysaccharide conjugate vaccine, composed of capsular epitopes from 
serotypes Ia, Ib, and III.(54) Accurate data on the incidence, risk factors, disease burden and 
outcomes of GBS in infants is critical to guide local and national policy focusing on a new 
immunisation program targeting this disease. Therefore, the aim of the current study was to 
identify the true incidence and disease burden of EOGBS and LOGBS infection in SA and NT, 
as well as help to identify any risk factors predisposing newborns to these infections. Such data 
are critical for the calculation of cost-effectiveness estimates for a funded immunisation 
program in Australia. 
 
PATIENT AND METHODS 
The study objectives are: 
(1) To determine the risk factors for neonatal GBS in an Australian population, and  
(2) To determine the true incidence of early onset and late onset GBS in SA and NT 
This case control study was conducted at the Women’s and Children’s Hospital, the Lyell 
McEwin Hospital, Flinders Medical Centre in SA and the Royal Darwin Hospital and Alice 
Springs Hospital, NT. Retrospective data was collected for the period 2000-2015.  
 
Clinical cases were identified by searching pathology databases for GBS positive sterile site 
specimens from children aged less than 90 days at diagnosis as well as identifying cases using 
the “ICD 10 CODE P36.0: Sepsis of newborn due to streptococcus, group B” and then a case 
note audit was performed.   
 
Cases were classified using an adapted case definition from the Ontario Public Health 
Standards Infectious Disease Protocol case definition (99) with a “confirmed GBS case” defined 
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as an infant whom has GBS cultured from a normally sterile site, with clinically compatible 
signs and symptoms of invasive disease up to 90 days after birth.  Clinically compatible signs 
and symptoms were characterised as having either: (1) early onset disease (<7 days), 
characterised by sepsis, pneumonia, meningitis, osteomyelitis or septic arthritis OR (2) late 
onset disease (≥7 days to 90 days), characterised by sepsis and meningitis. Clinical details 
during admission and up to 1 year of life were collected on all GBS cases via medical case note 
and pathology database audit. 
 
A “probable GBS case” was defined as an infant with clinically compatible signs and 
symptoms and a diagnosis of neonatal GBS disease in a newborn up to 90 days after birth, 
whose mother has laboratory confirmation of Group B streptococcus from a lower vaginal or 
anorectal specimen. Probable, or clinically suspected, GBS cases were included to ensure 
completeness of reporting in cases where an infant is treated early with antibiotics before all 
the appropriate specimens have been taken.  
 
Control infants were identified in a 2:1 ratio from the hospital birth register, with one control 
born as soon as possible before the case and a second control as soon as possible after the case, 
with both infants the same gender and in the same birth weight category as the case. Potential 
control infants were excluded if they had clinical evidence of sepsis during the first 90 days of 
life, ascertained during medical case note and pathology database audit.  
 
Multivariable logistic regression analyses were performed based on risk factors that have 
previously been shown to be associated with neonatal GBS infection. In addition, the true 
incidence of GBS in SA and NT was determined comparing the incidence ascertained during 
the audit and comparing to the total number of live births in SA and NT obtained from the 
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Australian Bureau of Statistics. To assess any association between the risk factors and neonatal 
GBS disease, logistical regression models were applied to report odds ratios with 95% 
confidence intervals.  A sample size of approximately 70 cases and 140 controls (1:2 matched 
design) was calculated to provide 100% power to detect an odds ratio of 6.88 for maternal GBS 
carriage(27) assuming 20% maternal GBS carriage (57) and 98% power to detect an odds ratio of 
4.17 for maternal infection (27) assuming 10% maternal infection (95) . 
 
A total of 353,081 (30,533 of Aboriginal and Torres Strait Islander (ATSI) origin) live births 
occurred in SA and NT over the study period. (100) Based on 2012 data, the Women’s and 
Children’s Hospital, Flinders Medical Centre, and Lyell McEwin Hospital sites account for 
approximately 53% of births in SA, representing 28%, 19%, and 14% of Aboriginal infant 
births in SA. (100) In the NT, the Royal Darwin Hospital and Alice Spring Hospital sites made 
up approximately 67% of all births, with 35% and 55% Aboriginal infant births in NT 
respectively. With a conservative estimate of 11 per 100,000 live births for early onset disease 
and 8 per 100,000 live births for late onset disease based on APSU data,(92)  we expected 
approximately 40 early-onset neonatal GBS sepsis cases and 29 late onset GBS cases over the 
16-year study period.  
 
Ethical approval for the study was obtained from the South Australian Aboriginal Health 
Research Ethics (Reference Number 04-16-663) Committee, the Women’s and Children’s 
Health Network Human Research Ethics Committee (HREC/16/WCHN/025), the Central 
Australian Human Research Ethics Committee (HREC-16-388), and the Human Research 
Ethics Committee of the Northern Territory Department of Health and Menzies School of 









INCIDENCE OF GBS 
During the 16-year study period, 219 cases of proven and probable GBS disease were 
identified. Of this total 79 cases (36.1%) had proven culture-positive EOGBS disease, and 60 
cases (27.4%) had proven culture-positive LOGBS disease. There were 12 cases (5.5%) that 
had probable GBS disease with a negative maternal swab for GBS, and 49 cases (22.4%) had 
probable GBS disease with a positive maternal swab for GBS. There were 19 cases (8.7%) of 
probable GBS disease where a maternal swab was unknown. When these clinically suspected 
cases were stratified into early-onset and late-onset GBS disease, the total number of cases of 
early-onset disease was 154 cases (70.3%) and late-onset disease was 65 cases (29.7%) in SA 
and NT. 
 
Using the number of live births identified from the Australian Bureau of Statistics in SA over 
the study period as 303,453 live births, the SA incidence (of probable and confirmed cases) 
was 32 cases per 100,000 for early onset GBS disease and 17.8 cases per 100,000 live births 
for late onset disease. The number of live births identified from the Australian Bureau of 
Statistics in NT over the study period as 61,628 live births. Therefore, the incidence (of 
probable and confirmed cases) in the NT was 92.5 cases per 100,000 live births for early onset 
GBS disease and 17.8 cases per 100,000 live births for late onset disease. 
 
When probable cases were removed the adjusted SA incidence for EOGBS was 18.1 per 
100,000 live births and for LOGBS was 17.5 per 100,000 live births, and NT incidence for 
EOGBS was 35.7 per 100,000 live births and for LOGBS was 14.6 per 100,000 live births. 
  







Univariate conditional analysis of maternal and labour risk factors (Table 2) identified the 
strongest independent risk factors associated with GBS disease. These included: known 
maternal GBS carriage, previous baby with GBS, previous fetal death (death at any gestation 
during pregnancy), maternal chorioamnionitis, prolong rupture of membranes > 18 hrs, and 
mode of delivery (vaginal delivery and Caesarean section with labour).  Similarly, 
multivariable analysis (Table 3) demonstrated that the strongest independent risk factors 
associated with GBS disease were also known maternal GBS carriage, previous fetal death 
(death at any gestation during pregnancy), maternal chorioamnionitis or intrapartum fever, with 
the use of maternal antibiotics found to be a protective factor. 
 
Multivariable analysis was performed to see whether risk factors exerted a different magnitude 
of effect according to the age at onset of GBS disease (Table 4). The strongest independent risk 
factors discriminating the likelihood of having late onset disease compared to early-onset 
disease were being a female infant, non-Indigenous status, and low birthweight. 
 
 
A description of the respective clinical features for early onset disease and late onset disease 
infants can be seen in Tables 5 to 7.  Infants with LOGBS were more likely to require 
intubation, have a longer stay in hospital, have a co-infection and less likely to be discharged 
breastfeeding compared to infants with EOGBS. During this study, 11 out of our 24 neonatal 
deaths were attributed to GBS infection, and during data collection of GBS isolates there were 









Incidence of GBS 
 
Despite the introduction of GBS screening program and maternal IAP use, it is clear the 
incidence and disease burden of GBS in South Australia and the Northern Territory is still 
significant. Furthermore, we identified a high incidence of EOGBS in the NT compared to 
APSU rates, which did not include NT data in their original study.(84) This highlights potential 
geographical differences in Australia with implications for future refinements in the clinical 
management of this significant disease, including any future antenatal GBS vaccination 
program.  
 
While a recent prospective surveillance study conducted in the United Kingdom (UK) over 
2014-2015 showed that the incidence of GBS disease was actually increasing, and that the 
burden of disease was not declining despite national screening and prevention guidelines, (80) 
previous Australian studies have reported falls in the incidence of EOGBS in particular. This 
difference may be due to the fact that in SA and NT the approach employs both universal 
screening vaginal swabs and the risk-based approach, whereas the UK have only adopted the 
risk-based screening approach. (22-24) In the Netherlands, where a risk based approach is 
applied, the rising incidence of GBS disease was attributed to a rise in the number of cases 
caused by GBS belonging to a specific GBS serotype III (clonal complex 17) and a decrease 
in a specific GBS serotype III (clonal complex 19), resulting in largely the same distribution 
of GBS serotype III before and after the introduction of IAP. (2)  
 
The incidence of probable and proven EOGBS cases in the NT was higher in this study 
compared to previous Australian data. Previous Australian studies have reported a fall in the 
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incidence of EOGBS. (82, 84) While the APSU study was conducted between 2005-2008 at 12 
major public hospitals across Australia, (84) it did not include the NT. Further, the authors 
concluded that clinicians only reported about one-third of known GBS cases in this time, 
indicating the importance of having multiple sources of surveillance in national studies. (84)  
This study captured both laboratory data and clinician reported GBS cases and covered a 16-
year time frame, thus providing a more reliable estimate of the true incidence of GBS disease. 
The high incidence of EOGBS in the NT indicates that there are likely geographical and 
potentially socioeconomic factors that may predispose this area to higher areas of disease. 
Antenatal attendance did not differ between our GBS cases and control groups so remoteness 
and access to antenatal clinics in the NT was not likely to be a factor. When evaluating use of 
IAP in SA, 38% of pregnant mothers of infants with GBS disease who had prolonged rupture 
of membranes received antibiotics in labour compared to 47% of mothers in the NT, thus 
antibiotic usage does not seem to be an explanation for increased EOGBS, and in fact IAP was 
shown to be a protective factor in this study, as supported by previous findings. (101)   In fact, 
there appeared to be more judicious use of antibiotics in the NT with only 15% of mothers in 
the control group receiving antibiotics compared to 34% of control mothers in SA. As our study 
did not collect data on GBS strain, more virulent strains in NT resistant to penicillin may 




In general, the risk factors identified for EOGBS and LOGBS in this study where identical to 
those already known which included: maternal GBS carriage, intrapartum fever/ 
chorioamnionitis, prolonged rupture of membranes, prematurity, previous baby with GBS and 
low birth weight.(27)  Previously known risk factors such as young maternal age and black 
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ethnicity groups were not identified during this study.(27)  However, the current data did identify 
additional factors not currently recognised in current screening protocols, such as previous fetal 
death. Previous fetal death has been shown in a study conducted in 2013 to be a risk factor for 
GBS (102) and in a systematic review conducted in 2013 GBS was responsible for causing 
stillbirth worldwide, with up to ‘12.1% proportion of stillbirth attributable to GBS in at least 
one low‐income country’. (103) 
 
During multivariable analysis, maternal IAP was found to be a protective factor against 
neonatal GBS disease, which can be expected as antibiotics are used to prevent the onset of 
neonatal GBS disease with this finding seen in other studies where the use of maternal IAP was 
‘linearly associated with decreasing EOGBS’. (101)   Despite the use of maternal antibiotics 
appearing to have a protective effect on the infant developing neonatal GBS in our study, the 
long term implications of widespread IAP include disruption of neonatal microbiota which may 
increase their risk of ‘coeliac disease, atopy, type 1 diabetes, obesity and asthma’ (85) and thus 
should be administered thoughtfully and according to current guidelines only.  
 
Studies conducted in the United States of America (USA) have shown black ethnicity groups 
have a higher incidence of neonatal GBS, (27) however in Australia there is no conclusive 
evidence to say whether being an Aboriginal or Torres Strait Islander (ATSI) individual, is an 
additional risk factor for maternal GBS colonisation or neonatal GBS disease. A study 
conducted in Western Australia over the years 1980-1998 showed that ‘Indigenous infants were 
more likely to die in-utero or postnatally’ than their non-Indigenous counterparts, with the 
‘highest relative risks seen in the potentially preventable category of infections’.(104) A study 
conducted in 1995 showed that Aboriginal Australians have a three times higher rate of GBS 
than non-Aboriginal infants (5.2 per 1000 births vs 1.7 per 1000 infants) and found that 
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Aboriginal infants had the highest rates of GBS disease in the world, the authors concluding 
that these findings were determined not to be related to prematurity but conceded that they did 
not collect data on GBS colonisation in Aboriginal women. (14)   
 
ATSI status was not identified as a risk factor for GBS in this study unlike previous studies, 
(14)  but it was shown that ATSI infants were more likely to have EOGBS compared to LOGBS. 
Our study did not find that ATSI mothers were more likely to be colonised with GBS than non-
ATSI mothers and further evaluation into colonisation and GBS virulence strains is warranted 
amongst this cohort. Similarly, studies conducted in Townsville did not find that Aboriginal 
newborns were more at risk of neonatal sepsis (28) and a NZ study showed that Maori and 
Pacific Island infants were not at greater risk of GBS infection. (105)  While the data for this 
specific population group appears conflicting, if ATSI status was proven to be a risk factor for 
GBS in the future, this cohort would be an ideal group for an antenatal GBS vaccination 
programme. 
 
One potential new direction for the management of this important perinatal complication is 
maternal GBS vaccination. A GBS vaccination program would likely be generally acceptable 
to pregnant Australian women, as there are already successful pertussis and influenza vaccine 
programs for this cohort whereby vaccination is primarily to protect the infant.(98) It is 
becoming increasingly apparent that a future vaccination program is be the most effective 
approach to lowering the incidence and disease burden of LOGBS. Maternal IAP has made a 
significant impact in decreasing neonatal morbidity and mortality due to EOGBS but it has not 
reduced the incidence or burden of LOGBS. (106) A study in the UK showed that a GBS 
vaccination program would prevent about twice as many cases of death and disability in the 
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neonate as microbiological screening, and three times as many as risk factor-based 
screening.(87) A vaccination program could also contribute to the avoidance of bacterial 
antibiotic resistance (29) and unwanted future health risks in infants caused by microbiota 
disturbance.(85) Other potential vaccination benefits include the prevention of preterm labour 
caused by GBS as well as reduced stillbirth rates caused by GBS infection.(29) 
 
A number of factors make GBS a suitable target for an immunisation program. GBS is a gram-
positive encapsulated coccus which occurs in pairs or short chains which shares a common 
‘Lancefield group B polysaccharide antigen.  It is further distinguished on the basis of type-
specific CPS into ten antigenically unique types (Ia, Ib, II-IX)’. (4, 44)  95% of infant and maternal 
GBS disease is caused by only five capsular polysaccharide serotypes: Ia, Ib, II, III and V’ (45, 
46), and several studies indicate that protective human immunity is associated with sufficient 
amounts of maternal antibodies to CPS serotypes Ia, Ib, III and V.(47) CPS serotype III is a 
major cause of neonatal disease, and is particularly associated with neonatal GBS meningitis.(9) 
As a result this serotype has become a popular vaccination target. However, the current vaccine 
preparations are based on serotypes and multi-locus sequencing types that are especially 
prevalent in the USA and Europe but not necessarily elsewhere in the world.(89)  
 
Currently, GBS vaccine development has only advanced to phase 1b/II trials by vaccine 
manufacturer Novartis/GSK (55) with a trivalent (Ia, Ib, and III) GBS polysaccharide conjugate 
vaccine. (56) In 2017 the vaccine manufacturer Pfizer started phase 1 trials to assess a 
pentavalent GBS polysaccharide targeting GBS serotypes Ia, Ib, II, III, and V. (57) CPS-based 
vaccines alternatives based on antigenic proteins have been explored, but these are restricted 
to particular serotypes and offer no complete cross-serotype protection. (107) Multi-genomic 
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approaches have already identified new GBS proteins and may be the answer to future GBS 
vaccine development. (89) 
 
Currently the obstacles to vaccine production include collating the most prevalent GBS 
serotypes and sequence types in all the regions of the world, and developing a vaccine that will 
have global benefit, offering the most cross-serotype protection. (89) Further Australian data on 
GBS serotypes is required in order to contribute towards vaccine and policy development. In 
terms of economic viability of such a programme, further Australian studies are necessary to 
ascertain whether it is economically viable to implement a GBS vaccination programme to 
pregnant women. However, a 2018 UK study clearly established cost-effectiveness of such a 
vaccination programme when considering the cost and the burden of invasive GBS disease. (88) 
 
This study has a number of limitations. The study was retrospective study design and a 
prospective study of risk factors would ensure more complete data collection. Further, 
retrospective data collection is associated with a greater risk of missing data, with pertinent 
information often not included in medical notes resulting in a reliance on the accuracy of 
clinicians’ data entries and the availability of results on pathology databases. Another study 
limitation was that the small numbers of patients identified in the NT made it difficult to match 
every case for gender and weight category (particularly in the case of very premature or low 
birthweight infants as these were often transferred interstate to major tertiary centres for 
ongoing care).  Finally, we did not evaluate which specific GBS strains were responsible for 
GBS disease burden, and in future this serological information would be very relevant to 
determine what strains are more prevalent in NT vs SA and better inform future vaccine 
development. 
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It is also important to highlight that whilst probable cases were included in the data collection 
stage of the study to calculate incidence of GBS, they were excluded in data analysis of risk 
factors to ensure the validity of the data. Exclusion of probable cases when evaluating risk 
factors ensured a more robust data set in an era of IAP where many infants who clinically have 
EOGBS disease have negative blood cultures due to the sensitivity of newborn blood cultures 
being low, which is further compounded by the use of maternal antibiotics in labour. (108)  
However, by excluding probable cases from data analysis, this may have influenced the 






At present neonatal GBS disease is not a notifiable disease and there are sparse data on 
incidence and disease burden in Australian infants. In addition, data on GBS affecting 
Aboriginal and Torres Strait Islander infants is similarly limited. (75-77) This study identified 
that in addition to prior known risk factors, ‘previous fetal death’ should be considered a risk 
factor neonatal GBS infection, and maternal antibiotics a protective factor against neonatal 
GBS disease.  The incidence of EOGBS in the NT appears much higher than the national 
average and would potentially benefit from a future maternal GBS vaccination programme, 
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TABLES 
Table 1: Description of proven GBS cases and control cases in SA and NT 
 




 N=139 ** N=264** 
SA Hospitals 108/139 (77.7) 210/264(79.5) 
Flinders Medical Centre 31/139 (22.3) 59/264 (22.3) 
Lyell McEwin Hospital 8/139 (5.8) 16/264 (6.1) 
Women’s & Children’s Hospital 69/139 (49.6) 135/264 (51.1) 
NT Hospitals 31/139 (22.3) 54/264 (20.5) 
Alice Springs Hospital 9/139 (6.5) 18/264 (6.82) 
Royal Darwin Hospital 22/139 (15.8) 36/264 (13.6) 
EOGBS*  (Confirmed in SA) 55/139 (55.4)  
EOGBS*  (Confirmed in NT) 22/139 (15.8)  
LOGBS* (Confirmed in SA) 53/139 (38.1)  
LOGBS* (Confirmed in NT) 9/139 (6.5)  
Mother’s mean age at delivery (SD) 28.5 years (6.0) 28.8 years (6.0) 
Gestational age   
Prematurity (< 37 weeks) 63/138 (45.7) 111/264 (42.0%) 
Term infants 75/138 (54.3) 153/264 (58.0%) 
Birth weight, mean (SD) 2486g (1184g) 2565g (1138g) 
< 1500g  41/135 (30.4) 71/264 (26.9) 
1500 – 2499 g 19/135 (14.1) 37/264 (14.0) 
≥ 2500g 75/135 (55.6) 156/264 (59.1) 
Sex   
Female 62/139 (44.6%) 124/264 (47%) 
Male 77/139 (55.4%) 140/264 (53%) 
*EOGBS = Early-onset Group B Streptococcus; LOGB = Late-onset Group B Streptococcus, † Clinically 
suspected and probable cases were not included in the statistical analysis, they were included in the 
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Table 2: Maternal and perinatal risk factors using conditional univariate analysis of proven GBS 
cases  
 




Odds ratio  
(95% CI)  
P value 
 
 (N=139) ** (N=264) **   
Age, median (SD)  28 (6.0) 28.8 (6.0) 0.99 (0.95 to 1.02) 0.52 
Aboriginal or Torres Strait Islander 24/136 (17.6) 32/258 (12.4) 1.54 (0.85 to 2.75) 0.15 
Maternal smoking     
Non-smoker 15/49 (30.6) 25/93 (26.9)  0.89* 
Current smoker  26/49 (53.1) 52/93 (55.9) 0.82 (0.37 to 1.85)  
Past smoker 8/49 (16.3) 16/93 (17.2) 0.85 (0.28 to 2.44)  
First-time pregnancies  40/125 (32.0) 91/259 (35.1) 0.86 (0.54 to 1.35) 0.51 
Multiparous mothers  73/128 (57.0) 137/259 (52.9)   1.20 (0.78 to 1.84) 0.41 
Prematurity (< 37 weeks) 63/138 (45.7) 111/264 (42.0) 1.25 (0.57 to 2.73)  0.58 
GBS bacteriuria† 0/139 (0) 3/264 (1.1)   
GBS carrier 40/91 (44.0) 28/170 (16.5) 4.16 (2.32 to 7.58) <0.001 
Previous baby with GBS infection  4/129 (3.1) 1/263 (0.4) 8.58 (1.25 to 168.98) 0.028 
Previous fetal death  12/128 (9.4) 8/263 (3.0) 3.26 (1.31 to 8.56) 0.012 
Maternal fever/ chorioamnionitis  39/94 (41.5) 19/224 (8.5) 8.75 (4.65 to 17.10) <0.001 
Rupture of membranes ≥ 18 hours 30/125 (34.3) 32/258 (13.6) 2.21 (1.27 to 3.86) <0.001 
Maternal antibiotics in labour 41/115 (35.7) 78/261 (29.9) 1.27 (0.79 to 2.04) 0.33 
Antibiotics 4 hrs prior to delivery  23/122 (18.9) 56/261 (21.5)   0.78 (0.44 to 1.34) 0.37 
Method of delivery      
Caesarean section without labour 16/133 (12.0) 75/260 (28.8)  <0.001* 
Vaginal delivery 87/133 (65.4) 134/260 (51.5) 3.58 (1.93 to 6.97)  
Caesarean section with labour 30/133 (22.6) 51/260 (19.6) 2.95 (1.46 to 6.11)  
* Global p-value, † Unable to calculate due to small numbers and wide range of error (Too few 
positive GBS bacteriuria results to fit a logistic regression model and obtain a reliable estimate of the 
odds ratio.) **A difference in denominator indicates missing data 
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Table 3: Multivariable conditional logistic regression analysis of risk factors 
 
 Odds ratio (95% CI) P value 
Sex   
Male  0.86 
Female 0.92 (0.39 to 2.16)  
Maternal Group B streptococcus carriage    
No  <0.001 
Yes 6.53 (2.46 to 18.4)  
Previous fetal death   
No  0.01 
Yes 8.11 (1.63 to 43.3)  
Suspected maternal chorioamnionitis   
No  <0.001 
Yes 28.1 (9.87 to 93.8)  
Maternal antibiotics in labour   
No  0.04 
Yes 0.36 (0.11 to 0.95)  
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Table 4: Multivariable conditional logistic regression analysis: discrimination between late onset 
disease versus early onset disease 
 
 Odds ratio (95% CI) P value 
Maternal GBS carriage   
No  0.002 
Yes 0.03 (0.0007 to 0.31)  
Suspected maternal chorioamnionitis    
No  0.80 
Yes 0.81 (0.14 to 4.35)  
Duration of rupture of membranes    
< 18 hours  0.56 
≥ 18 hours 0.50 (0.039 to 4.98)  
Sex   
Male  0.03 
Female 7.02 (1.18 to 61.13)  
Aboriginal or Torres Strait Islander    
No  0.01 
Yes 0.06 (0.003 to 0.5)  
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Table 5. Clinical Features between EOGBS & LOGBS cohort* (Proven and Probable cases) 




 (n = 154) (n =65) 
Temperature instability T < 36.5 32/154 (21) 19/65 (29) 
Pyrexia ≥ 37.5 55/154 (36) 25/65 (39) 
Vomiting 5/154 (3) 10/65 (15) 
Poor feeding 23/154 (15) 21/65 (32) 
Irritable/unsettled infant 23/154 (15) 24/65 (37) 
Abdominal Distension 4/154 (5) 6/65 (11) 
Cyanosis 30/154 (20) 6/65 (11) 
Respiratory distress 100/154 (65) 42/65 (65) 
Apnoea 30/154 (20) 24/65 (37) 
Bradycardia 26/154 (17) 18/65 (28) 
Poor peripheral perfusion 59/154 (38) 22/65 (34) 
Hypotension 25/154 (16) 7/65 (11) 
Unexpected need for resuscitation 44/154 (29) 3/65 (5) 
Hypoglycaemia 38/154 (25) 9/65 (14) 
Lethargy 26/154 (17) 21/65 (32) 
Seizures 7/154 (5) 10/65 (15) 
Capillary refill time > 2 seconds 20/154 (13) 7/65 (11) 
Metabolic and/or respiratory acidosis 49/154 (32) 10/65 (15) 
Tachycardia 16/154 (10) 19/65 (29) 
Shock 13/154 (8) 1/65 (2) 
Persistent fetal circulation 7/154 (5) 0/65 (0) 
Disseminated intravascular coagulation 2/154 (1) 1/65 (2) 
Overall Clinical Presentation(s)   
Sepsis 109/154 (71) 58/65 (89) 
Meningitis 11/154 (7) 15/65 (23) 
Pneumonia 60/154 (39) 10/65 (15) 
Other invasive disease 12/154 (8) 6/65 (9) 
Mean White Cell Count (x109/L)    
EOGBS n = 140; LOGBS n=63 13.3 (95% CI, 11.1 to 15.4) 10.2 (95% CI, 8.6 to 11.7) 
Mean Total Neutrophil Count (x109/L)   
EOGBS n = 125; LOGBS n=55 5.3 (95% CI, 4.5 to 6.2) 5.1 (95% CI, 4.0 to 6.2) 
Mean Total Band Count (x109/L)   
EOGBS n = 125; LOGBS n=56 1.7 (95% CI, 1.2 to 2.1) 2.1 (95% CI, 0.04 – 4.1) 
Mean Band neutrophil ratio [I/T ratio] (%)   
EOGBS n = 125; LOGBS n=55 26.5 (95% CI, 22.2 to 30.8) 19.1 (95% CI, 15.2 to 23.1) 
Gastric aspirate microscopy positive   
Yes 17/154 (11.0) 1/65 (1.5) 
No 1/154 (0.6) 0/65 (0) 
Unknown/Not done 136/154 (88.3) 64/65 (98.4) 
Urine latex GBS agglutinins positive   
Yes 38/154 (24.7) 3/65 (4.6) 
No 19/154 (12.3) 10/65 (15.4) 
Unknown/Not done 97/154 (63.0) 52/65 (80.0) 
* EOGBS = Early-onset Group B Streptococcus; LOGB = Late-onset Group B Streptococcus; **A difference 
in denominator indicates missing data 
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Table 6: Clinical details of cases EOGBS vs LOGBS*  
 
 Odds ratio (95% CI) P value 
Respiratory distress   
EOGBS  0.44 
LOGBS 0.76 (0.38 to 1.53)  
Required intubation or ventilation   
EOGBS  <0.001 
LOGBS 3.2 (1.60 to 6.70)  
Baby required intensive care or high dependency   
EOGBS  0.06 
LOGBS 1.94 (0.98 to 3.92)  
Number of days in hospital **   
EOGBS, mean 14.8 days (SD 19.3)  <0.001 
LOGBS, mean 67.3 days (SD 107) RR 4.54 (3.29 to 6.29)  
Age at disease (days) **   
EOGBS, mean 0.62 days (SD 1.2)   <0.001 
LOGBS, mean 41.7 days (SD 26) RR 66.84 (46.31 to 98.35)  
Neonatal death due to GBS infection   
EOGBS  0.32 
LOGBS 1.99 (0.53 to 9.57)  
Sterile site blood culture or PCR positive   
EOGBS  0.86 
LOGBS 0.78 (0.03 to 19.91)  
Sterile site CSF culture or PCR positive   
EOGBS  0.009 
LOGBS 4.43 (1.43 to 16.73)  
Co-infections   
EOGBS  <0.001 
LOGBS 3.42 (1.65 to 7.25)  
Discharged exclusive breast feeding   
EOGBS  0.003 
LOGBS 0.31 (0.14 to 0.67)  
* EOGBS = Early-onset Group B Streptococcus; LOGB = Late-onset Group B Streptococcus ** Note 
that a negative binomial regression model was fitted & the estimate and CI provided are a Rate Ratio 
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Table 7. Burden of disease between EOGBS & LOGBS cohorts during admission and at 1 year of 
life* (Proven and Probable Cases) 




 (n = 154) ** (n =65) ** 
Complications within acute infection   
Pneumonia 16/154 (10) 9/65 (14) 
Focal skin or soft tissue infection 8/154 (5) 5/65 (8) 
Focal infection of urinary tract 2/154 (1) 1/65 (2) 
Meningitis 3/154 (2) 2/65 (3) 
Developmental delay 0/154 (0) 3/65 (5) 
Spastic quadriplegia 3/154 (2) 1/65 (2) 
Seizures  6/154 (4) 5/65 (15) 
Cortical blindness 1/154 (1) 1/65 (2) 
Deafness 0/154 (0) 1/65 (2) 
Periventricular Leukomalacia 2/154 (1) 3/65 (5) 
Complications present in first year of life   
Pneumonia 2/154 (1) 1/65 (2) 
Focal bone infection/osteomyelitis 1/154 (<1) 2/65 (3) 
Focal skin or soft tissue infection 3/154 (2) 0/65 (0) 
Focal infection of urinary tract 3/154 (2) 0/65 (0) 
Meningitis 2/154 (1) 0/65 (0) 
Developmental delay 7/154 (5) 6/65 (9) 
Spastic quadriplegia 0/154 (0) 1/65 (2) 
Microcephaly 0/154 (0) 1/65 (2) 
Seizures 1/154 (1) 2/65 (3) 
Cortical blindness 1/154 (1) 1/65 (2) 
Deafness 1/154 (1) 2/65 (3) 
Periventricular Leukomalacia 3/154 (2) 2/65 (3) 
* EOGBS = Early-onset Group B Streptococcus; LOGB = Late-onset Group B Streptococcus;  
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The main objective of this study was to measure the true incidence of neonatal GBS disease in South 
Australia and the Northern Territory, and to identify any risk factors for GBS disease. Additionally, the 
study sought to provide a description of the clinical features of EOGBS and LOGBS and GBS disease 
burden in Australia. Unfortunately, neonatal GBS sepsis and meningitis is not a notifiable disease, with 
notification to the APSU conducted on individual discretion of the treating clinician. As a result, there is 
limited data on disease incidence in Australian infants, and data on GBS affecting Aboriginal and 
Torres Strait Islander infants is similarly limited (75-77). Although IAP has made a significant impact in 
decreasing EOGBS neonatal morbidity and mortality, it has not reduced the incidence or burden of late 
onset GBS disease (31), which theoretically may only be decreased with the institution of a maternal 
immunization programme in pregnancy. Mandatory notification of this disease would enable us to 
collect accurate data of disease incidence and burden of disease across Australia, which would help 
immensely with categorisation of GBS strain and virulence factors and help inform future vaccine 
development with up to date and cohesive Australian data. 
 
Whilst there is worldwide data available on the incidence of maternal GBS colonisation and neonatal 
EOGBS and LOGBS disease, there has been a lack of Australian data in the last decade. There is also 
a shortage of data specifically in relation to the Aboriginal & Torres Strait Islander population, with 
conflicting information in the past regarding whether Aboriginality is an additional risk factor for neonatal 
GBS infection or not. A study conducted in 1995 postulated that Aboriginality may be a potential risk 
factor, showing that Aboriginal Australians have higher rate of GBS than non-aboriginal infants (5.2 per 
1000 vs 1.7 per 1000 infants) (106) .  
 
On evaluation of both probable and proven cases, this study found a surprisingly high incidence of 
EOGBS in the Northern Territory, 98 per 100,000 live births which is much higher than the national 
average provided by the APSU of 38 per 100,000 live births with LOGBS. Probable GBS cases were 
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included in the study to determine the incidence of GBS disease and to ensure completeness of 
reporting in cases where an infant is treated early with antibiotics before all the appropriate specimens 
have been taken, which can often occur in the era of universal neonatal GBS screening programmes 
and the administration of IAP. Australia currently has successful pertussis and influenza vaccine 
programs for pregnant mothers, where vaccination is given to mothers primarily to protect the unborn 
infant, and thus it can be assumed a similar antenatal GBS vaccination program will be acceptable to 
the Australian population. 
 
Future Australian studies are required to ascertain whether this higher incidence of EOGBS in the NT is 
valid, and if so, what changes in policy and practice could provide could reduce this incidence. From 
our retrospective study it did not appear that the NT used IAP less than the SA cohort, and in fact the 
opposite was identified as 25% of NT mothers whose infants had neonatal GBS disease received 
antibiotics at least 4 hours prior to baby delivery from onset of ROM, compared to 15.9% of SA mothers 
whose infants had neonatal GBS disease. However, if looking at overall rate of antibiotics given to 
mothers in labour (including those that received them less than 4 hours prior to their infant was born) 
this was only given to 37.7% SA mothers with GBS infants and 47% of NT mothers respectively, and 
thus the increased usage of IAP in the NT compared to SA.  
 
Traditionally, benzyl penicillin is used as IAP and is administered at least 4 hours before delivery. 
Despite the fact that 4 hours has been found to be highly effective at preventing EOGBS in clinical 
trials, it has been proposed in some studies that even 1-2 hours may confer some benefit to the 
neonate as well but may not be as affective at preventing EOGBS. (31) The use of maternal IAP in the 
NT was higher than use of maternal IAP in SA, and thus IAP does not account for the higher incidence 
of probable and confirmed cases of EOGBS in the NT. One might conclude there may be a 
geographical factors to GBS disease such as antibiotic resistance, or strains of GBS that are more 
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virulent dependent on local geography, or a higher force of infection, carriage density or prolonged 
carriage. Further studies would be required to evaluate this in the future as to whether there are more 
virulent strains in the NT compared to SA, less sensitive to maternal IAP.  
 
A future antenatal vaccination program is likely to be the feasible option in the future for lowering the 
incidence and disease burden of LOGBS. Worldwide universal screening and maternal IAP has made a 
significant impact in decreasing neonatal morbidity and mortality due to EOGBS, but it has unfortunately 
has not reduced the incidence or burden of LOGBS (106) . A vaccination program would help prevent avoid 
the development of antibiotic resistant bacteria (29) and unwanted future health risks in infants caused by 
microbiota disturbance (85). Other vaccination benefits include preventing preterm labour caused by GBS 
as well as stillbirths caused by GBS infection, and the prevention of allergic reactions caused by 
antibiotics (29). 
 
 Whilst there may be clinician bias when interpreting whether infants had clinical signs of GBS disease 
in the absence of laboratory confirmation, these infants on medical notes review had several indicators 
of sepsis clinically and thus ‘probable cases’ of GBS disease were included in the study for incidence 
calculation. However, these probable cases were not included in the statistical analysis when 
determining risk factors for early and late onset in order to ensure that the data analysis remained 
robust based on laboratory confirmation.  When probable cases were removed the adjusted SA 
incidence for EOGBS was 18.1 per 100,000 live births and for LOGBS was 17.5 per 100,000 live births, 
and NT incidence for EOGBS was 35.7 per 100,000 live births and for LOGBS was 14.6 per 100,000 
live births, in this instance both EOGBS and LOGBS are both lower than the proposed APSU national 
average of 32 per 100,000 live births for early-onset and 17.8 per 100,000 live births. (84) Further 
studies are required to investigate whether this lower incidence represents clinicians’ adherence to 
GBS screening and IAP treatment guidelines, or whether it is due to geographical or maternal factors.  
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Prior to this study, known risk factors for EOGBS disease included: maternal GBS carriage, intrapartum 
fever and maternal chorioamnionitis, prolonged rupture of membranes, prematurity, low birth weight, 
young maternal age, black ethnicity groups (based on studies conducted in the USA), previous baby 
with GBS, and low levels of GBS anticapsular antibody.  (27) Risk factors for LOGBS are less well-
defined in literature, however nosocomial and maternal sources have been implicated (27).  From this 
study maternal age, ethnicity, maternal smoking status, poor antenatal attendance, maternal drug use, 
and number of prior pregnancies did not appear to be risk factors for neonatal GBS disease. We were 
unable to ascertain if GBS bacteriuria was a risk factor for GBS (likely due to lack of data), although it is 
acknowledged that women with GBS bacteriuria are presumed to be colonised with GBS and managed 
accordingly during pregnancy. (109)   
 
From previously published literature maternal age and prematurity are known risk factors for GBS 
disease (27) which was not identified in this study, perhaps due to small numbers of cases. This study 
was similarly not able to elucidate if sex, ATSI status or premature labour were risk factors for GBS 
disease compared to the control group, however it did identify that male and female infants both had a 
50% chance of having EOGBS, with males slightly higher chance of LOGBS (55.4% vs 44.6%). ATSI 
infants had a higher chance of EOGBS than LOGBS (25.3% vs 12.3%) when both groups were 
compared. Although this study was not able to determine if being Aboriginal or Torres Strait Islander 
predisposes to GBS neonatal infection our data suggests a trend with a higher odds ratio for disease in 
Aboriginal infants. 
 
Interestingly, infants below 1.5 kg tended to have LOGBS rather than EOGBS (55.4% vs 18.1%) and 
those above 3.5 kg tended to have EOGBS rather than LOGBS (33.1% vs 11.1%); whilst infants of low 
birth weight are often premature, we cannot assume this of the entire cohort as some term infants may 
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be affected by intrauterine growth restriction and thus be small for gestational age. Prematurity may not 
have been found to be a risk factor in this study for GBS due to the sample size restrictions from 
several hospital sites, especially of that in the NT, where very premature infants are often transferred in 
utero to tertiary centres interstate for pending delivery. The results in the study regarding the risk factor 
of prematurity may have arisen due to the small numbers of patients identified in the NT which made it 
impossible to match every case for gender and weight category (particularly in the case of very 
premature or low birthweight infants as these were often transferred interstate to major tertiary centres 
for ongoing care). 
 
From this study risk factors for GBS disease included: maternal GBS carriage, previous fetal death (in 
this study defined as death at any gestation during pregnancy), maternal chorioamnionitis, and as one 
would assume, with maternal antibiotics in labour appearing to be a protective risk factor against 
neonatal GBS disease. Previous fetal death appears to be a new risk factor for GBS disease which 
should be highly recommended in guideline development of risk factors in future antenatal screening 
protocols.   
 
This study was only able to comment on burden of disease if patients re-presented to any of the 5 
hospitals involved in data collection the first year of life. As a result, there is a possibility that this data is 
incomplete and GBS is responsible for higher rates of complications than was ascertained during this 
study. It was found that infants with LOGBS were more likely than EOGBS to have focal bone infection 
or osteomyelitis (3.1% vs 0.6%), developmental delay (9.2% vs 4.5%), spastic quadriplegia (1.5% vs 
0%), seizures (3.1% vs 0.6%), cortical blindness (1.5% vs 0.6%), and deafness (3.1% vs 0.6%). 
Paradoxically in our study, infants with EOGBS were more likely to present in the first year of life after 
discharge with meningitis than LOGBS (1.3% vs 0%). 
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Whilst maternal IAP continues to be a protective factor against neonatal GBS disease, the widespread 
use of IAP is already concerning for the development of resistant strains of GBS and non-GBS 
pathogens and should not be the default approach to management of GBS in the future. It is apparent 
from this study that the burden of early and late onset GBS disease in our Australian population is still 
prevalent despite the introduction of GBS screening programmes and maternal IAP use. A prospective 
surveillance study conducted in the UK showed the incidence of GBS disease was increasing, and that 
the burden of disease was not declining despite national screening and prevention guidelines. (80)  A 
recent study conducted in the UK in 2018 has established cost-effectiveness of such a vaccination 
programme when considering the cost and the burden of invasive GBS disease, (88) but further 
Australian studies are required to ascertain whether it is cost-effective based on these results for 
implementation of a GBS vaccination programme to pregnant women. Other rare but debilitating 
diseases are being considered for immunisation programs in young infants such as meningococcal 
disease.  Further research is required to determine the specific strains of GBS causing disease in 
infants in different Australian regions to help determine an effective maternal GBS vaccine to prevent 
potentially devastating neonatal GBS infections. 
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SUMMARY & RECOMMENDATIONS 
 
In summary, the results of this study provide three recommendations: 
 
 
1. A recommendation that all Australian states and territories move towards a mandatory 
reporting system for neonatal GBS early onset and late onset disease, and to formally collect 
data on any associated neonatal morbidity and mortality in order to ascertain the true incidence 




2. A recommendation for previous fetal death to be included as a risk factor to current GBS 
screening guidelines alongside previously known risk factors. 
 
 
3. A recommendation to consider a national GBS vaccination program for pregnant women, once 
a safe and effective GBS vaccine becomes available, particularly for at risk pregnant women, 
based on risk factors such as prior foetal death.  This would potentially improve pregnancy 
outcomes and is likely be acceptable to the Australian women given the successful introduction 
of similar vaccination programmes for influenza and pertussis where the primary aim is to 
confer neonatal immunity when given to mothers during pregnancy.  
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The benefits of a GBS vaccination program include but are not limited to: decreasing the 
incidence of late onset GBS, which has remained steady despite the introduction of GBS 
screening programs and reduced use of maternal intrapartum antibiotics, and potential 
eradication of early and late onset GBS including serious neurodevelopmental sequelae. An 
immunisation program for pregnant women would potentially prevent preterm labour as well as 
stillbirths caused by GBS infection, and prevent side effects caused by antibiotics such as 
allergic reactions and the development of antibiotic resistant bacteria and unwanted future 
health risks in infants caused by microbiota disturbance such as gastrointestinal conditions and 
atopic diseases such as asthma.  
 
 
Implementation of these 3 recommendations has the potential to eliminate neonatal GBS 
disease but further Australian data will be required regarding GBS serotype and geographical 
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SOUTH ASUTRALIAN PERINATAL PRACTICE GUIDLELINES: GROUP B STEPTOCOCCAL OBSTETRIC 
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